Currently, only Lumakras (Sotorasib, Amgen), approved by the FDA on May 28, 2021, is used to treat patients with a proto-oncogene KRAS G12C-mutated NSCLC, the first targeted drug approved for KRAS mutations [107]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.